1. ¹Department of Environmental and Occupational Health Sciences, University of Washington, School of Public Health and Community Medicine, Seattle, WA, USA
2. ²Department of Epidemiology, University of Washington, School of Public Health and Community Medicine, Seattle, WA, USA
3. ³Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
4. ⁴Center for Health Studies, Group Health Cooperative, Seattle, WA, USA

Correspondence: Dr D Fulton-Kehoe, Department of Environmental and Occupational Health Sciences, University of Washington, School of Public Health and Community Medicine, Seattle, WA, USA. E-mail: debfk@u.washington.edu

Received 2 December 2005; Revised 27 January 2006; Accepted 27 January 2006; Published online 7 March 2006.

Abstract

Although associations have been reported between antidepressant use and risk of breast cancer, the findings have been inconsistent. We conducted a population-based case–control study among women enrolled in Group Health Cooperative (GHC), a health maintenance organization in Washington State. Women with a first primary breast cancer diagnosed between 1990 and 2001 were identified (N=2904) and five controls were selected for each case (N=14396). Information on antidepressant use was ascertained through the GHC pharmacy database and on breast cancer risk factors and screening mammograms from GHC records. Prior to one year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio=1.06, 95% CI 0.94–1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR=0.98, 95% CI 0.80–1.18). There also were no differences between cases and controls with regard to the number of prescriptions filled or the timing of use. Taken as a whole, the results from this and other studies to date do not indicate an altered risk of breast cancer associated with the use of antidepressants overall, by class, or for individual antidepressants.